Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD
Bart J. Kramers, Iris W. Koorevaar, Maatje D.A. van Gastel, et al.
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 4, pp. 507-517
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Olivier Devuyst, Curie Ahn, Thijs R.M. Barten, et al.
Kidney International (2025) Vol. 107, Iss. 2, pp. S1-S239
Open Access | Times Cited: 4
How Does ADPKD Severity Differ Between Family Members?
Klement C. Yeung, Elise Fryml, Matthew B. Lanktree
Kidney International Reports (2024) Vol. 9, Iss. 5, pp. 1198-1209
Open Access | Times Cited: 6
Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease
Thomas Bais, Ron T. Gansevoort, Esther Meijer
Drugs (2022) Vol. 82, Iss. 10, pp. 1095-1115
Open Access | Times Cited: 24
The Effect of Thiazide Diuretics on Urinary Prostaglandin E2 Excretion and Serum Sodium in the General Population
Frank Geurts, Crissy F Rudolphi, Anissa Pelouto, et al.
The Journal of Clinical Endocrinology & Metabolism (2024) Vol. 109, Iss. 10, pp. 2444-2451
Open Access | Times Cited: 5
Treatment of Autosomal Dominant Polycystic Kidney Disease
Sara S. Jdiaa, Reem A. Mustafa, Alan S.L. Yu
American Journal of Kidney Diseases (2024)
Open Access | Times Cited: 5
The evaluation of clinical factors affecting oral health impacts on the quality of life of Iranian elderly patients visiting dental clinics: A cross‐sectional study
Nazanin Mirhosseini, Reyhaneh Shoorgashti, Simin Lesan
Special Care in Dentistry (2024) Vol. 44, Iss. 4, pp. 1219-1227
Closed Access | Times Cited: 4
Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
Matthew Gittus, Helen Haley, Tess Harris, et al.
BMC Nephrology (2025) Vol. 26, Iss. 1
Open Access
Hypertension in Cystic and Polycystic Kidney Disease
Juan Villa, Álvaro Álvarez, Nicolás Roberto Robles
Updates in hypertension and cardiovascular protection (2025), pp. 63-78
Closed Access
Paradoxical Anti-diuretic Effects of Thiazide and Thiazide-Like Diuretics in Diabetes Insipidus: A Systematic Review
Anne Laure Annaïck Perrine, Driti Reechaye, Indrajit Banerjee, et al.
Cureus (2025)
Open Access
Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon
Julie Zhou, Vicente E. Torres
Advances in Kidney Disease and Health (2023) Vol. 30, Iss. 3, pp. 245-260
Closed Access | Times Cited: 7
HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial
Thomas Bais, Esther Meijer, Bart J. Kramers, et al.
Trials (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
A child with TSC2/PKD1 contiguous gene deletion syndrome successfully treated with tolvaptan for rapidly enlarging renal cysts
Chika Muroga, Hiroki Yokoyama, Ryo Kinoshita, et al.
CEN Case Reports (2024) Vol. 13, Iss. 5, pp. 351-355
Open Access | Times Cited: 2
Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights
Irene Capelli, Sarah Lerario, Francesca Ciurli, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 5, pp. 469-484
Closed Access | Times Cited: 2
Cross-Species Insights into Autosomal Dominant Polycystic Kidney Disease: Provide an Alternative View on Research Advancement
Jianing Luo, Yuan Zhang, Sakthidasan Jayaprakash, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5646-5646
Open Access | Times Cited: 2
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Kitty St Pierre, Brydee Cashmore, Davide Bolignano, et al.
Cochrane library (2024) Vol. 2024, Iss. 10
Closed Access | Times Cited: 2
Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort
Luca Calvaruso, Kevin Yau, Pedram Akbari, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Interaction Between Determinants Governing Urine Volume in Patients With ADPKD on Tolvaptan and its Impact on Quality of Life
Polina Todorova, Sita Arjune, Claudia Hendrix, et al.
Kidney International Reports (2023) Vol. 8, Iss. 8, pp. 1616-1626
Open Access | Times Cited: 4
Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease
Frank Geurts, Laixi Xue, Bart J. Kramers, et al.
Clinical Journal of the American Society of Nephrology (2023) Vol. 18, Iss. 11, pp. 1426-1434
Open Access | Times Cited: 4
Autosomal Dominant Polycystic Kidney Disease: Is There a Role for Autophagy?
Claudio Ponticelli, Gabriella Moroni, Francesco Reggiani
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14666-14666
Open Access | Times Cited: 4
Long-term effect of increasing water intake on repeated self-assessed health-related quality of life (HR-QoL) in autosomal dominant polycystic kidney disease
Gopala K. Rangan, Margaret Allman‐Farinelli, Neil Boudville, et al.
Clinical Kidney Journal (2024) Vol. 17, Iss. 7
Open Access | Times Cited: 1
Regional variation in tolvaptan prescribing across England: national data and retrospective evaluation from an expert centre
Jiehan Chong, Tess Harris, Albert Ong
Clinical Kidney Journal (2022) Vol. 16, Iss. 1, pp. 61-68
Open Access | Times Cited: 6
Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment
Pattareeya Yottasan, Tifany Chu, Parth D. Chhetri, et al.
Translational research (2023) Vol. 265, pp. 17-25
Closed Access | Times Cited: 3
Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease
William Ackley, Neera K. Dahl, Meyeon Park
Advances in Kidney Disease and Health (2023) Vol. 30, Iss. 3, pp. 228-235
Closed Access | Times Cited: 2
Clinical findings, underlying pathogenetic processes and treatment of vascular dysfunction in autosomal dominant polycystic kidney disease
Jinjun Zhu, Fei Liu, Jianhua Mao
Renal Failure (2023) Vol. 45, Iss. 2
Open Access | Times Cited: 2
Thiazides in kidney transplant recipients: skin in the game
Steven Van Laecke
Nature Reviews Nephrology (2024) Vol. 20, Iss. 6, pp. 351-352
Closed Access
Page 1 - Next Page

Scroll to top